Fingolimod: advantages for some children and adolescents with highly active RRMS

June 24, 2019

Since 2018, the immunosuppressant drug fingolimod has also been approved for children and adolescents aged 10 years and older whose relapsing remitting multiple sclerosis (RRMS) is highly active or severe and rapidly evolving. In an early benefit assessment conducted in the beginning of 2019, the German Institute for Quality and Efficiency in Health Care (IQWiG) had investigated whether the drug has an added benefit for these patients. No added benefit was proven for three of four patient groups; a hint of a non-quantifiable added benefit was found for the fourth group.

Added benefit in health-related quality of life

In the course of the hearing at the Federal Joint Committee (G-BA), the manufacturer of the drug subsequently submitted data from the study on which its dossier was based. The G-BA therefore commissioned IQWiG to analyse these data in an addendum. Now it was also possible to analyse the data on the outcome "health-related quality of life" for young patients with highly active RRMS who need to switch their basic therapy: Whereas children and adolescents in the comparator arm reported a worsening in their quality of life at the end of the study, there was clear improvement in the fingolimod arm. This resulted in a hint of an added benefit.

No relevant differences in cognitive function

The original dossier additionally lacked detailed results on cognitive function testing in the subjects. The study used five tests, which together covered all core areas of cognitive functioning. However, only two of them were used in all study centres: In the Symbol Digit Modality Test, subjects were asked to use a simple code table to match digits to specific symbols; in the test on so-called visual-motor integration, children traced simple shapes such as crosses or circles. Hence, not all core domains of cognition are covered anymore and the results are therefore not informative. Regardless of this, there were no relevant differences between the study arms anyhow.

"The addendum has not changed the overall conclusion on added benefit", says Stefan Lange, Deputy Director of IQWiG. "But we are pleased that we have been able to see informative data on health-related quality of life here. This is an extremely important treatment effect particularly for patients so young."

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the manufacturer's dossier and the IQWiG dossier assessment, the manufacturer submitted additional information in the commenting procedure. The G-BA subsequently commissioned IQWiG to assess the data subsequently submitted. IQWiG now presents this assessment in the form of an addendum. The G-BA makes a final decision on the extent of added benefit.
-end-


Institute for Quality and Efficiency in Health Care

Related Children Articles from Brightsurf:

Black and Hispanic children in the US have more severe eczema than white children
A presentation at this year's virtual American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting reveals the disparities that exist for Black and Hispanic children when it comes to Atopic Dermatitis (AD), commonly known as eczema.

Black children with cancer three times less likely to receive proton radiotherapy than White children
A retrospective analysis led by investigators from Brigham and Women's Hospital has found racial disparities in the use of the therapy for patients enrolled in trials.

The Lancet Child & Adolescent Health: First Europe-wide study of children confirms COVID-19 predominately causes mild disease in children and fatalities are very rare
Children with COVID-19 generally experience a mild disease and fatalities are very rare, according to a study of 582 patients from across Europe published today in The Lancet Child & Adolescent Health journal.

Children not immune to coronavirus; new study from pandemic epicenter describes severe COVID-19 response in children
- While most children infected with the novel coronavirus have mild symptoms, a subset requires hospitalization and a small number require intensive care.

How many children is enough?
Most Russians would like to have two children: a boy and a girl.

Preterm children have similar temperament to children who were institutionally deprived
A child's temperament is affected by the early stages of their life.

Only-children more likely to be obese than children with siblings
Families with multiple children tend to make more healthy eating decisions than families with a single child.

Children living in countryside outperform children living in metropolitan area in motor skills
Residential density is related to children's motor skills, engagement in outdoor play and organised sports. that Finnish children living in the countryside spent more time outdoors and had better motor skills than their age peers in the metropolitan area.

Hispanic and black children more likely to miss school due to eczema than white children
In a study that highlights racial disparities in the everyday impact of eczema, new research shows Hispanic and black children are more likely than white children to miss school due to the chronic skin disease.

Children, their parents, and health professionals often underestimate children's higher weight status
More than half of parents underestimated their children's classification as overweight or obese -- children themselves and health professionals also share this misperception, according to new research being presented at this year's European Congress on Obesity (ECO) in Glasgow, UK (April 28-May 1).

Read More: Children News and Children Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.